To compare the urinary pH, recurrence-free survival, and safety of adjuvant intravesical therapy in non-muscle invasive bladder cancer (NMIBC) patients receiving mitomycin C (MMC) therapy and MMC + cytosine arabinoside (Ara-C) therapy.
To compare the urinary pH, recurrence-free survival, and safety of adjuvant intravesical therapy in non-muscle invasive bladder cancer (NMIBC) patients receiving mitomycin C (MMC) therapy and MMC + cytosine arabinoside (Ara-C) therapy.